Transcriptomic landscape of breast cancers through mRNA sequencing

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Eswaran, Jeyanthy ^a,b   Cyanam, Dinesh ^a   Mudvari, Prakriti ^a,b   Reddy, Sirigiri Divijendra Natha ^b   Pakala, Suresh B ^b   Nair, Sujit S ^b   Florea, Liliana ^c   Fuqua, Suzanne A W ^d   Godbole, Sucheta ^a   Kumar, Rakesh ^a,b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TRANSCRIPTOME;

ARTICLE; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; PATHOLOGY; POLYMERASE CHAIN REACTION; REGULATORY SEQUENCE; VALIDATION STUDY;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; POLYMERASE CHAIN REACTION; REGULATORY SEQUENCES, NUCLEIC ACID; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84859786122     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00264     Document Type: Article

References (63)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
2. Vargo-Gogola, T. & Rosen, J. M. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7, 659-672 (2007). (Pubitemid 47327411)
3. Reis-Filho, J. S. & Lakhani, S. R. Breast cancer special types: why bother? J Pathol 216, 394-398 (2008).
4. Geyer, F. C., Marchio, C. & Reis-Filho, J. S. The role of molecular analysis in breast cancer. Pathology 41, 77-88 (2009).
5. Weigelt, B. & Reis-Filho, J. S. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6, 718-730 (2009).
6. Geyer, F. C., Lopez-Garcia, M. A., Lambros, M. B. & Reis-Filho, J. S. Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med 13, 4090-4103 (2009).
7. Buerger, H. et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 189, 521-526 (1999).
8. Buerger, H. et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 194, 165-170 (2001). (Pubitemid 32519965)
9. Stingl, J. & Caldas, C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7, 791-799 (2007). (Pubitemid 47463670)
10. Brenton, J. D., Carey, L. A., Ahmed, A. A. & Caldas, C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23, 7350-7360 (2005). (Pubitemid 46202348)
11. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006). (Pubitemid 44571966)
12. Oakman, C., Santarpia, L. & Di Leo, A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 7, 725-732 (2010).
13. Andre, F. & Pusztai, L. Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. Pharm Res 23, 1951-1958 (2006).
14. Elston, C. W., Ellis, I. O. & Pinder, S. E. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 31, 209-223 (1999). (Pubitemid 29424143)
15. Soerjomataram, I., Louwman, M. W., Ribot, J. G., Roukema, J. A. & Coebergh, J. W. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107, 309-330 (2008). (Pubitemid 351172108)
16. Dawson, S. J., Provenzano, E. & Caldas, C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45 Suppl 1, 27-40 (2009).
17. Rakha, E. A. et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26, 3153-3158 (2008).
18. Weigelt, B., Geyer, F. C. & Reis-Filho, J. S. Histological types of breast cancer: how special are they? Mol Oncol 4, 192-208 (2010).
19. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
20. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869-10874 (2001). (Pubitemid 32878711)
21. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100, 8418-8423 (2003). (Pubitemid 36842560)
22. Rakha, E. A., Reis-Filho, J. S. & Ellis, I. O. Basal-like breast cancer: a critical review. J Clin Oncol 26, 2568-2581 (2008).
23. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999-2009 (2002). (Pubitemid 35461656)
24. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
25. van 't Veer, L. J. et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res 5, 57-58 (2003).
26. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27, 1160-1167 (2009).
27. Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet 365, 671-679 (2005). (Pubitemid 40260888)
28. Naderi, A. et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26, 1507-1516 (2007). (Pubitemid 46340809)
29. Sgroi, D. C. Preinvasive breast cancer. Annu Rev Pathol 5, 193-221 (2010).
30. Weigelt, B., Baehner, F. L. & Reis-Filho, J. S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 220, 263-280 (2010).
31. Pusztai, L., Mazouni, C., Anderson, K., Wu, Y. & Symmans, W. F. Molecular classification of breast cancer: limitations and potential. Oncologist 11, 868-877 (2006). (Pubitemid 44373759)
32. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109, 1721-1728 (2007). (Pubitemid 46668532)
33. Carey, L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13, 2329-2334 (2007). (Pubitemid 46698581)
34. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. NEngl J Med 363, 1938-1948 (2010).
35. Finnegan, T. J. & Carey, L. A. Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol 3, 55-63 (2007).
36. Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13, 4429-4434 (2007). (Pubitemid 47219710)
37. Gusterson, B. A. Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. Eur J Cancer 28, 263-267 (1992).
38. Gusterson, B. A. et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10, 1049-1056 (1992).
39. Badve, S. et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24, 157-167 (2011).
40. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5, 621-628 (2008). (Pubitemid 351911867)
41. Haas, B. J. & Zody, M. C. Advancing RNA-Seq analysis. Nat Biotechnol 28, 421-423 (2010).
42. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
43. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28, 511-515 (2010).
44. Santos, G. C., Zielenska, M., Prasad, M. & Squire, J. A. Chromosome 6p amplification and cancer progression. J Clin Pathol 60, 1-7 (2007). (Pubitemid 46142665)
45. Richard, F. et al. Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 89, 305-310 (2000). (Pubitemid 30430749)
46. Seute, A. et al. Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. Int J Cancer 93, 80-84 (2001). (Pubitemid 32539505)
47. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol 11, R106 (2010).
48. Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res 19, 1639-1645 (2009).
49. Licatalosi, D. D. & Darnell, R. B. RNAprocessing and its regulation: global insights into biological networks. Nat Rev Genet 11, 75-87 (2010).
50. Watkins, G., Douglas-Jones, A., Bryce, R., Mansel, R. E. & Jiang, W. G. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 72, 267-272 (2005). (Pubitemid 40342998)
51. Morabito, A. et al. Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and beta2-microglobulin downregulation in breast cancer. Hum Immunol 70, 492-495 (2009).
52. Ricolleau, G. et al. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6, 1963-1975 (2006).
53. Cao, X. X. et al. RACK1: A superior independent predictor for poor clinical outcome in breast cancer. Int J Cancer 127, 1172-1179 (2010).
54. Moore, L. E. et al. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer (2011).
55. Williams, D. B. Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum. J Cell Sci 119, 615-623 (2006).
56. Sorlie, T. et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7, 127 (2006).
57. Hu, Z. et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006).
58. Garber, M., Grabherr, M. G., Guttman, M. & Trapnell, C. Computational methods for transcriptome annotation and quantification using RNA-seq. Nat Methods 8, 469-477 (2011).
59. Ozsolak, F. & Milos, P. M. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 12, 87-98 (2011).
60. Watkins, G., Martin, T. A., Bryce, R., Mansel, R. E. & Jiang, W. G. Gamma-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells. Prostaglandins Leukot Essent Fatty Acids 72, 273-278 (2005). (Pubitemid 40342999)
61. Cao, X. X. et al. RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway. Breast Cancer Res Treat 126, 555-563 (2011).
62. Cao, X. X. et al. RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat 123, 375-386 (2010).
63. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).